ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.147,42
-0,65%
S&P 500
6.037,88
0,72%
US Dollar vs BRL
5,801
0,74%
Bitcoin
97.919,39
0,06%
Brent Oil
75,525
-0,55%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kymera Therapeutics Inc (KYMR)

  7. Kymera Therapeutics Inc (KYMR) Notícias

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KYMR
DataHoraFonteTítuloCódigoCompanhia
30/01/202509:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming February Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
14/01/202518:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
14/01/202509:00GlobeNewswire Inc.Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
13/01/202509:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
07/01/202509:00GlobeNewswire Inc.Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14NASDAQ:KYMRKymera Therapeutics Inc
26/11/202409:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming December Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
05/11/202409:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
31/10/202409:13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:KYMRKymera Therapeutics Inc
31/10/202408:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KYMRKymera Therapeutics Inc
31/10/202408:30GlobeNewswire Inc.Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
24/10/202408:00GlobeNewswire Inc.Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory DiseasesNASDAQ:KYMRKymera Therapeutics Inc
23/10/202408:15GlobeNewswire Inc.Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31NASDAQ:KYMRKymera Therapeutics Inc
23/10/202408:00GlobeNewswire Inc.Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 SymposiumNASDAQ:KYMRKymera Therapeutics Inc
09/10/202408:00GlobeNewswire Inc.Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 DegraderNASDAQ:KYMRKymera Therapeutics Inc
25/09/202408:00GlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV CongressNASDAQ:KYMRKymera Therapeutics Inc
28/08/202408:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming September Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
21/08/202412:15GlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
20/08/202417:31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
19/08/202423:45GlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $225 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
19/08/202417:01GlobeNewswire Inc.Kymera Therapeutics Announces Proposed Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
07/08/202408:00GlobeNewswire Inc.Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
31/07/202408:00GlobeNewswire Inc.Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7NASDAQ:KYMRKymera Therapeutics Inc
16/07/202417:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
09/07/202408:00GlobeNewswire Inc.Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation DayNASDAQ:KYMRKymera Therapeutics Inc
09/07/202407:54IH Market NewsBP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More NewsNASDAQ:KYMRKymera Therapeutics Inc
08/07/202417:05GlobeNewswire Inc.Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and EfficacyNASDAQ:KYMRKymera Therapeutics Inc
14/06/202408:00GlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
01/06/202409:00GlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
29/05/202408:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
23/05/202418:00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KYMR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RCSL4
RECRUSUL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AMAR3
LOJAS MARISA ON
BOV
RPMG3
PET MANGUINH ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios